Marinus Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and thank you for joining us. My name is Ting Zhang. I'm a healthcare banker here at JPMorgan. Before we begin, I just want to quickly remind our audience to please feel free to submit your questions using the blue button on your screen. We'll address them during Q&A. In addition, the presentation slides are available on your screen. With that, I'm pleased to introduce this session's presenters, Dr. Scott Braunstein, CEO; and Mr. Steve Pfanstiel, CFO of Marinus Pharmaceuticals. Without further ado, I'll let Scott and Steve take it away.
Thanks, Ting. Good morning, everyone. I'm Scott Braunstein, the CEO of Marinus Pharmaceuticals. I'm going to walk you through our presentation today. On Slide 2, you will see our safe harbor statement, not going to spend too much time there.
On Slide 3, you'll see a little bit of an overview of what we're doing at Marinus. Ganaxolone is our lead compound. It's a positive allosteric modulator at the GABAA receptor.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |